EQS-Adhoc: Pentixapharm Holding AG: Rights offering successfully completed, remaining shares available for subscription through private placement

Publication of Inside Information pursuant to Article 17 of Regulation (EU) No. 596/2014

Pentixapharm Holding AG: Rights offering successfully completed, remaining shares available for subscription through private placement

• Gross issue proceeds of EUR 16.8 million from the rights offering alone (including oversubscription)
• Private placement of up to 1,923,441 remaining New Shares runs until 28 July 2026
• From the Management Board’s perspective, a good starting point for partnership and out-licensing discussions

Ad hoc announcement pursuant to Article 17 MAR

Berlin, July 22, 2026 – Pentixapharm Holding AG has completed the rights offering conducted in connection with the capital increase announced on 1 July 2026. Subscription rights were exercised for the issuance of 9,096,771 new shares, including the option offered to shareholders to acquire additional new shares by way of the so-called oversubscription. This corresponds to a proportion of 82.5% of the total planned volume of the capital increase.

As a result of the rights offering alone (including the so-called oversubscription), the Company will thus receive gross issue proceeds of approximately EUR 16.8 million. The Company intends to use the net proceeds from the offering primarily to finance key steps of the PANDA Phase 3 study, as well as for further corporate development and expansion in the U.S. market. In the Management Board’s assessment, this provides the Company with a good starting point for the intensified evaluation of partnership and out-licensing options, in particular in the United States.

The remaining, 1,923,441 unsubscribed new shares will be offered to institutional investors until 28 July 2026 by way of a private placement in Germany and certain other jurisdictions outside the Federal Republic of Germany at a placement price in the amount of the subscription price of EUR 1.85 per new share.

In addition to financing the PANDA study, part of the net issue proceeds is intended to be used for the Company’s further development and expansion into the US market, as well as for further preparation of clinical development and to strengthen manufacturing and supply infrastructure. This is intended to support the late-stage clinical development of the Company’s programs and further build the foundation for possible future commercialization.

July 22, 2026

Pentixapharm Holding AG, Berlin

The Management Board

Contact: ir@pentixapharm.com

Important Notice: This announcement does not constitute an offer to sell or a solicitation of an offer to purchase or subscribe for any securities. Any public offering will be made solely on the basis of the published subscription offer and the Annex IX document. This announcement is not intended for publication, distribution or release in or into the United States of America, Australia, Canada, Japan or any other jurisdiction where such publication, distribution or release would be unlawful.

The new shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (“Securities Act”), and may not be offered or sold in the United States of America or to, or for the account or benefit of, U.S. persons absent registration under, or an applicable exemption from the registration requirements of, the Securities Act. There will be no public offering of the shares in the United States of America.

2369974  22-Jul-2026 CET/CEST